J Donald Easton1, Maria Aunes2, Gregory W Albers2, Pierre Amarenco2, Sara Bokelund-Singh2, Hans Denison2, Scott R Evans2, Peter Held2, Marianne Jahreskog2, Jenny Jonasson2, Kazuo Minematsu2, Carlos A Molina2, Yongjun Wang2, K S Lawrence Wong2, S Claiborne Johnston1. 1. From Department of Neurology, University of California, San Francisco (J.D.E.); AstraZeneca, Gothenburg, Sweden (M.A., S.B.-S., H.D., P.H., M.J., J.J.); Stanford University Medical Center, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology and Stroke Center, Bichat University Hospital and Medical School, Paris, France (P.A.); Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA (S.R.E.); National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (K.M.); Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain (C.A.M.); Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (Y.W.); Department of Medicine and Therapeutics, Chinese University of Hong Kong, China (K.S.L.W.); and Dean's Office, Dell Medical School, University of Texas, Austin (S.C.J.). jdonaldeaston@ucsf.edu clay.johnston@austin.utexas.edu. 2. From Department of Neurology, University of California, San Francisco (J.D.E.); AstraZeneca, Gothenburg, Sweden (M.A., S.B.-S., H.D., P.H., M.J., J.J.); Stanford University Medical Center, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology and Stroke Center, Bichat University Hospital and Medical School, Paris, France (P.A.); Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA (S.R.E.); National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (K.M.); Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain (C.A.M.); Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (Y.W.); Department of Medicine and Therapeutics, Chinese University of Hong Kong, China (K.S.L.W.); and Dean's Office, Dell Medical School, University of Texas, Austin (S.C.J.).
Abstract
BACKGROUND:Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). METHODS: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. RESULTS:A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52-1.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. CONCLUSIONS: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01994720.
RCT Entities:
BACKGROUND:Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). METHODS: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. RESULTS: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52-1.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. CONCLUSIONS: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01994720.
Authors: Holly Tillman; S Claiborne Johnston; Mary Farrant; William Barsan; Jordan J Elm; Anthony S Kim; Anne S Lindblad; Yuko Y Palesch; J Donald Easton Journal: JAMA Neurol Date: 2019-07-01 Impact factor: 18.302
Authors: K S Lawrence Wong; Pierre Amarenco; Gregory W Albers; Hans Denison; J Donald Easton; Scott R Evans; Peter Held; Anders Himmelmann; Scott E Kasner; Mikael Knutsson; Per Ladenvall; Kazuo Minematsu; Carlos A Molina; Yongjun Wang; S Claiborne Johnston Journal: Stroke Date: 2018-06-18 Impact factor: 7.914
Authors: Jildaz Caroff; Robert M King; Giovanni J Ughi; Miklos Marosfoi; Erin T Langan; Christopher Raskett; Ajit S Puri; Matthew J Gounis Journal: Neurosurgery Date: 2020-11-16 Impact factor: 4.654
Authors: S Claiborne Johnston; Pierre Amarenco; Hans Denison; Scott R Evans; Anders Himmelmann; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Yongjun Wang Journal: Int J Stroke Date: 2019-02-12 Impact factor: 5.266
Authors: K Y Park; T Ozaki; A Kostynskyy; H Kortman; A Hilario; P Nicholson; R Agid; T Krings; V M Pereira Journal: AJNR Am J Neuroradiol Date: 2021-07-08 Impact factor: 4.966
Authors: Pierre Amarenco; Hans Denison; Scott R Evans; Anders Himmelmann; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Yongjun Wang; S Claiborne Johnston Journal: Stroke Date: 2020-11-16 Impact factor: 7.914
Authors: Pierre Amarenco; Hans Denison; Scott R Evans; Anders Himmelmann; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Yongjun Wang; S Claiborne Johnston Journal: JAMA Neurol Date: 2020-11-07 Impact factor: 18.302
Authors: S Claiborne Johnston; Pierre Amarenco; Maria Aunes; Hans Denison; Scott R Evans; Anders Himmelmann; Marianne Jahreskog; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Sven Nylander; Joachim Röther; Yongjun Wang Journal: Stroke Date: 2021-09-03 Impact factor: 7.914